Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:CVRX

CVRx Q3 2026 Earnings Date & Estimates

CVRx logo
$1.45 +0.03 (+2.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.45 +0.00 (+0.14%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVRx is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from CVRx in Q3 2026

CVRx is expected to post earnings of -$0.49 per share on revenue of $13.93 million. In the same quarter a year earlier CVRx reported -$0.49 per share on revenue of $14.69 million. CVRx last reported on August 6, 2026, posting -$0.53 per share and missing the -$0.5246 consensus estimate. CVRx has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.49
Expected Revenue
$13.93 million
Prior-Year EPS
-$0.49
Prior-Year Revenue
$14.69 million
Expected Revenue Growth
-5.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.53 (Missed by -$0.0054)
Last Quarter Revenue
$15.71 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

CVRx Q3 2026 Earnings FAQ

CVRx (NASDAQ:CVRX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

CVRx's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect CVRx to post earnings of -$0.49 per share for Q3 2026.

The consensus revenue estimate for CVRx is $13.93 million for Q3 2026.

CVRx Earnings Headlines

CVRx, Inc. (CVRX) - What Are Investment Firms Saying About This Stock?
October 26 at 2:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31156728
CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386926/0/en/cvrx-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call-on-november-5-2026.html
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as January 27 and has put together a free presentation explaining what is happening inside and why the timing matters.tc pixel
October 26 at 1:00 AM  |  Paradigm Press (Ad)
Head-To-Head Review: CVRx (NASDAQ:CVRX) & Sanuwave Health (NASDAQ:SNWV)
October 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31125292
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
October 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hagens-berman-national-securities-law-firm-encourages-cvrx-inc-cvrx-investors-with-substantial-losses-to-contact-firm-investigating-potential-securities-fraud-following-59-stock-drop-302896315.html
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371349/0/en/cvrx-announces-late-breaking-data-and-new-clinical-evidence-on-barostim-at-the-hfsa-annual-scientific-meeting-2026.html
See More CVRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email.

About CVRx

CVRx (NASDAQ:CVRX) (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure. The system has received regulatory authorization in the United States for eligible heart failure patients and is also marketed in international regions for approved indications.

Founded in 2001 and headquartered in Minneapolis, Minnesota, CVRx sells its products through a combination of direct commercial operations and distributor relationships. The company works with hospitals, physicians and cardiovascular specialists in the United States and select markets outside the country. CVRx is led by President and Chief Executive Officer Kevin H. Ballinger.

View CVRx Profile
Earnings Tools